Mumbai , the commercial capital of India is all set to showcase the prowess of the generics capital of the world ,when the global pharma majors converge here for CPhI India, the largest and most comprehensive pharmaceutical industry event in South Asia.
As one of the strongest emerging markets in the global pharma industry, India presents great opportunities for all international pharmaceutical companies to explore and benefit from.
It is told that every fifth tablet, capsule and injectable in generics drugs consumed anywhere in the world is manufactured in India. India manufactures 30 per cent of the world requirement of anti-HIV drugs. India is now among the top five pharmaceutical emerging markets .
India has had an efficient pharmaceutical industry, which has been making affordable drugs not just for the Indian markets but has also been exporting them to the world. The Indian pharmaceutical industry is globally the third largest in terms of volume and 13th largest in terms of value, supplying around 10 per cent of total global production.
The industry grew at a CAGR of 12.5 per cent during the past five years and is expected to growth at a robust CAGR of 15.1 per cent during FY 2012-17 given huge export potential coupled with steady growth in the domestic formulation market.
This year alone, India’s pharma exports stand at some $14.7 billion (2012-2013), registering a growth rate of 11per cent, with 55 per cent of exports heading to highly regulated western markets. The Government has set a target of $ 25 billion for pharmaceutical exports by 2016.
Giving insights into the growth of APIs in India, Dr. Appaji, Director General, Pharmaceuticals Export Promotion Council of India (Pharmexcil) says, “The pharma industry in India is growing at 15 per cent annually since 2010 and is expected to reach an export target of US$ 18 billion by 2014. With growing generics markets across the world Indian pharmaceutical industry offers great opportunities, especially in API, outsourcing, generics and biosimilars.”
In support of these goals, Government of India has already put in place initiatives with the goal of cementing the country’s position as the Pharmacy of the World. The government has made tax breaks available to the pharmaceutical sector and a weighted tax deduction of 150 per cent for any R&D expenditure incurred. It has also introduced 19 dedicated Special Economic Zones to help stimulate pharma sector investment across the country. As a result of these initiatives, it is expected that R&D expenditure will continue to grow at an annualised rate of nearly 20 per cent for the next few years.
Indian pharma companies are constantly innovating and adopting international standards to stay relevant in the competitive global market. It is, therefore, not surprising that the Indian pharma sector received close to 40 per cent of all Abbreviated New Drug Approvals (ANDA) approvals from the US Food and Drug Administration (FDA) during January-July 2013.
“India’s pharma industry has undergone a sustained period of consolidated expansion, thanks to the government’s ability to facilitate policies and economic conditions that have fostered growth. This development is timely. When nations across the globe are grappling with increased resource requirements for growing healthcare needs, Indian pharma offers credible and affordable healthcare solutions ” says Aparna Dutt Sharma, CEO of Indian Brand Equity Foundation (IBEF).
“What is most remarkable about growth in our export of generics is not just the sheer numbers involved but thanks to our expertise, quality standards and cost effective manufacturing techniques, we have also been able to lower the cost of vital medicines in the developing world. The cost of HIV/AIDS treatment was lowered to $400 per year from $12,000,” says Sudhanshu Pandey, Joint Secretary, Department of Commerce, Ministry of Commerce and Industry, India.
As the pharma industry is increasingly looking towards India to source high-quality, low-cost pharma solutions, CPhI India 2013 would be the perfect platform for companies to pick up the latest trends and innovations the market has to offer. It enables them to meet the movers and shakers in India's pharma machinery, technology, ingredients, outsourcing and biopharma industry for a competitive advantage that will help grow your business.
The largest pharmaceutical industry event in South Asia, dedicated to the chemical and pharma ingredient industry , is slated to take place at the Bombay Exhibition Centre, between December 3 and 5, 2013.
Organised by UBM, the event would see around 900 exhibitors and 28,000 visitors from 95 countries, including China, the United States, the United Kingdom, France and Italy. The event would be co-located with other events like P-MEC: for pharmaceutical machinery, equipment and technology, ICSE: for pharmaceutical contract services and outsourcing solutions, BioPh :for bio-solutions for pharma, and CPhI conferences and seminars.
CPhI India provides opportunity to interact and network with industry players from pharmaceutical ingredients, machinery, equipment and technology, contract services and biopharma solutions.
The event would provide the right platform to the participants to showcase their products and services. Its aim is to bring together the top leaders of the industry into a single arena and set new standards and take the industry to the next level.
Says H Erik Heemskerk , Brand Director, Pharma Portfolio, UBM Live"All of our CPhI events offer the industry an ideal platform to invest in growing markets and they have been specifically selected to provide global opportunities to enhance the market. India is a very attractive platform for the pharmaceutical sector, having seen manufacturing innovation and development technologies rise- particularly thanks to the explosion in generics production".
The likely exhibitors include active pharmaceutical ingredients (APIs), alkaloids, amino acids, antibiotics, antibodies, antimicrobial preservatives, antioxidants, biocatalysts, biotechnology, capsules/encapsulation, chemical synthesis/analysis, chiral intermediates, coating agents, colour and dispersions, etc.
The event would provide them ample opportunities to meet major decision-makers and prospective clients dealing with pharma machinery, technology, ingredients, outsourcing and biopharma, and explore partnerships with key pharma companies from India and abroad.
The visitors would be able to source high-quality ingredients and services at competitive prices, learn about the latest innovations, technologies, trends and developments in India's pharmaceutical industry .
Says Erik Heemskerk "This year, P-MEC India retains its strength and has expanded to adopt an additional hall , which will attract more pharmaceutical machinery, technology and packaging exhibitors to the event, highlighting the growing role that this sector has and providing more business leads than ever before.
Furthermore, our mobile app which we launched last year will be available on all mobile devices with an internet connection, helping our attendees to navigate their way around the event, drive traffic to stands and stay up to date with schedules and speaker events.
Finally, ahead of this year’s event, the UBM India Pharma awards will be taking place on December 2, honouring and celebrating excellence and showcasing the crème de la crème of the Indian pharmaceutical industry. During this celebratory evening, there will be a panel discussion on “Moving up the Global Pharma Value Chain” designed to inform and educate those present at the ceremony. Nine awards will be given this year, including Excellence in Contract research and ‘Excellence in Packaging Development’. There will also be a lifetime achievement award, honouring a key player for their long-standing commitment to the shaping of the pharmaceutical industry.
According to Heemskerk ,CPhI India’s co-location with events P-MEC, ICSE and BioPh reflects current industry trends. The pharmaceutical machinery and equipment market in India is significantly growing and as such P-MEC India has rapidly expanded at the event, providing unprecedented insight into the equipment and machinery sector , highlighting the latest innovations and trends in the market.
Big pharma is increasingly turning to outsourcing solution providers and CROs meaning that outsourcing services offered at the show is becoming increasingly important for those attending. BioPh also is continually growing, showcasing the rise of the biopharmaceutical industry. This show has been designed to help continually foster the climate of innovation and growth within the sector, and has evolved to provide a platform for different stakeholders across each stage of the biopharma value chain to begin working together – whether from drug discovery, specialised clinical research organisations (CRO) or biotech and CMO. Both ICSE and BioPh exhibitors will be located within the CPhI hall this year.
Upbeat with the success of its iPHEX global event , the Pharmexcil will have an India pavilion at CPhI India.
"This is the seventh time such a big event happening in Mumbai and we want all our members to take part and gain the maximum from this opportunity,” says Dr PV Appaji.
The council has already reserved space a space of 972 square meters to accommodate more than 100 pharmaceutical companies to exhibit their products and services at the event.
The last year CphI India event could strengthen India’s reputation as one of the most important pharma markets. The event witnessed 28,182 attendees from 95 countries across the globe.
There was a large representation of visitors from Bangladesh, China, Germany, Indonesia, Italy, Japan, Korea, Nepal, Nigeria, Russian Federation, Thailand, UAE, UK and USA.
The event provided a platform that gave attendees an unrivalled opportunity to network with industry players from pharmaceutical ingredients, machinery, equipment & technology, contract services and biopharma solutions. There was an overwhelming response from exhibitors with 926 exhibitors from 21 countries participating at the exhibition. The number of exhibitors participation increased compared to last year thanks to an increase of stand space created for the P-MEC event.
Rajeev Kher, Additional Secretary, Department of Commerce, Ministry of Commerce and Industry, Government of India was the Guest of Honour. Concurrent with the exhibition, the first edition of CPhl India Pharma Awards 2012 was also held on November 21.
The first edition of the awards had seven broad categories including Innovation in Quality, Product Development, Cost, Environment and Health & Safety (EHS), together with the lifetime achievement and Pharma Personality of the Year awards. The process advisors of the awards were Ernst & Young. CPhl India Awards was supported by Pharmexcil and Brand India Pharma. The evaluation of the awards was done by an independent panel of senior industry professional.
Preceding the awards ceremony, CPhl and P-MEC India hosted the first ever CEO Conclave, bringing together pharma business with eminent scholars and industrial experts to engage and promote the development and growth of the Indian pharma industry. The CEO Conclave held a panel discussion on "Developing Capability, Credibility and Culture to integrate deeper into the global value chain for the Indian Pharma Industry" which was attended by more than 250 senior-most industry members. Technical seminars ran throughout the days of the exhibition, showcasing innovations and new developments in the pharma industry.
South Asia's largest pharma event offered a global platform for buyers and sellers from the pharma industry, enhanced their business prospects, established strategic alliances and helped with technology transfer. CPhl and P-MEC India paved the way for intra-industry co-operation and the success of the event bridged the gap between the international community and Indian enterprises, creating bigger business opportunities and showcasing India as a global pharma hub.
With continued growth in the API, generics, fine chemicals and bio-pharmaceuticals industries on the Indian sub-continent, CPhI India and related pharma services events saw about 20 per cent increase in exhibitors, coupled with a five per cent rise in attendees.